We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale

Product News   Mar 18, 2019

 
Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale

Image credit: Cellesce

FURTHER INFORMATION
 
 
 

Related Product News

Adaptate Biotherapeutics Formed To Develop T-cell Modulating Antibody-based Therapies

Product News

A new company aims to modulate γd T-cell activity using therapeutic antibodies, with the potential to trigger an immune response against cancer.

READ MORE

Promising Efficacy and Toxicity Data For New Antibody Drug Conjugate

Product News

Femtogenix has announced data verifying the favorable toxicity profile and potent efficacy of its Pyridinobenzodiazepine (PDD) antibody-drug conjugate payload platform in tumor cell models.

READ MORE

CombiGene Signs Agreement for Production of Gene Therapy Drug Candidate

Product News

CombiGene, a gene therapy company, has signed an agreement with Cobra for production of candidate drug CG01.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE